$ACT Company News Actavis expects profit to be
Post# of 74551
Posted On: 01/13/2015 12:09:13 PM
$ACT Company News
Actavis expects profit to beat expectations 9:44 a.m. Jan. 12, 2015 - Michael Calia
Drug trials, upgrades boost health-care sector 11:57 a.m. Jan. 8, 2015 - Russ Britt
10 stocks that can withstand a rocky 2015 12:31 p.m. Dec. 31, 2014 - The Trading Deck
Eight charts plot the year in finance 12:45 p.m. Dec. 30, 2014 - Ophir Gottlieb
Here are the best S&P 500 stocks and sectors of 2014 1:52 p.m. Dec. 29, 2014 - Philip van Doorn
2014 was the year that all predictions were wrong 11:29 a.m. Dec. 26, 2014 - Marek Fuchs
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Adamas' stock soars after dementia treatment approval 8:24 a.m. Dec. 24, 2014 - Tomi Kilgore
Second 2% S&P 500 spike signals strong bull trend 11:23 a.m. Dec. 19, 2014 - Michael Ashbaugh
What a week: Botox haze, merger Monday and The Tanned One 9:19 a.m. Nov. 21, 2014 - Marek Fuchs
Valeant's stock rises after new $2 billion buyback plan announced 12:00 p.m. Nov. 20, 2014 - Tomi Kilgore
La-Z-Boy shares rally after earnings beat targets 4:41 p.m. Nov. 18, 2014 - Sue Chang
S&P, Dow ring up records Tuesday 4:35 p.m. Nov. 18, 2014 - Barbara Kollmeyer
Actavis shares outpace buyout target’s gains 12:30 p.m. Nov. 18, 2014 - Russ Britt
S&P 500 registers 42nd record close in skittish market 4:59 p.m. Nov. 17, 2014 - Carla Mozee
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
Valeant says it won’t meet Actavis’s offer 12:18 p.m. Nov. 17, 2014 - Russ Britt
If you're looking big pharma, look no further than Actavis 11:33 a.m. Nov. 17, 2014 - The Trading Deck
Actavis to buy Allergan in $66 billion deal 9:35 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Actavis confirms to buy Allergan in $66 billion deal 9:30 a.m. Nov. 17, 2014 - Ciara Linnane
Celgene, Bristol-Myers Cancer Drug News Lifts Stocks 5:48 p.m. Jan. 12, 2015 - Investors Business Daily
Celgene Says Q4 Earnings Beat, Sees Currency Impact 12:52 p.m. Jan. 12, 2015 - Investors Business Daily
3 Stocks Advancing The Drugs Industry 12:13 p.m. Jan. 12, 2015 - TheStreet.com
Digging Deeper: Outperforming Stocks In The Leading Health Care Sector 12:10 p.m. Jan. 12, 2015 - Seeking Alpha
FTC grants early termination of HSR waiting period for Actavis/Allergan deal 9:34 a.m. Jan. 12, 2015 - Seeking Alpha
Actavis Profit to Beat Expectations 9:21 a.m. Jan. 12, 2015 - The Wall Street Journal Interactive Edition
Actavis (ACT) Off To A Strong Start In Pre-Market Activity 9:10 a.m. Jan. 12, 2015 - TheStreet.com
Four Best Gains In IBD 50: Nothing To Do With Oil 5:35 p.m. Jan. 9, 2015 - Investors Business Daily
Jim Cramer's 'Mad Money' Recap: You'll Make More Money Buying Into Panic 8:23 p.m. Jan. 8, 2015 - TheStreet.com
Four Hot Growth Stocks To Put On Your Watch List 5:06 p.m. Jan. 8, 2015 - Investors Business Daily
Adamas earns milestone from Actavis 4:19 p.m. Jan. 8, 2015 - Seeking Alpha
Actavis' Appeal Case for Namenda Gets Accelerated Hearing - Analyst Blog 4:35 p.m. Jan. 7, 2015 - Zacks.com
KaloBios Pharmaceuticals' KB001-A Fails Primary Endpoint - Analyst Blog 2:28 p.m. Jan. 7, 2015 - Zacks.com
10 Stocks Every Millennial Should Add to Their Portfolio Right Now 11:37 a.m. Jan. 7, 2015 - TheStreet.com
Health-Care Stocks Avoid Malaise 8:34 p.m. Jan. 6, 2015 - The Wall Street Journal Interactive Edition
Will Allergan Buy Help Actavis Extend Growth Streak? 5:17 p.m. Jan. 6, 2015 - Investors Business Daily
Merger Arbitrage Mondays - January 5, 2015 6:34 a.m. Jan. 5, 2015 - Seeking Alpha
IBD 50 Tone Darkens; More Leaders Below 10-Week Line 5:13 p.m. Jan. 2, 2015 - Investors Business Daily
An Investor's Guide: Market-Leading Industries In 2014 1:57 p.m. Jan. 2, 2015 - Investors Business Daily
Activists Are on a Roll, With More to Come 5:08 p.m. Jan. 1, 2015 - The Wall Street Journal Interactive Edition
Actavis Launches U.S. Generic Specialty Injectable Portfolio 8:00 a.m. Today - PR Newswire - PRF
Equities Updates on Health Care Sector - Johnson and Johnson, VIVUS, Actavis, Covance, and Sequenom 8:35 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis Announces Exceptional Preliminary Fourth Quarter 2014 Performance 8:30 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis’ Pending Acquisition of Allergan and Record Dates for Shareholder Meetings 8:02 a.m. Jan. 12, 2015 - BusinessWire - BZX
Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis' Pending Acquisition of Allergan and Record Dates for Shareholder Meetings 8:00 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis Confirms Appeals Court Grants Expedited Appeal of Ruling Requiring Continued Distribution of NAMENDA® IR 3:54 p.m. Jan. 6, 2015 - PR Newswire - PRF
Actavis and Gedeon Richter Announce FDA Receipt of NDA Resubmission for Cariprazine 2:00 a.m. Jan. 6, 2015 - PR Newswire - PRF
Timing is Crucial, Upside Analysis: Research Reports on Alder, Sky Solar, CNinsure, Raytheon, and Actavis 9:00 a.m. Dec. 29, 2014 - PR Newswire - PRF
Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 1:15 p.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride 8:00 a.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer 9:24 a.m. Dec. 22, 2014 - PR Newswire - PRF
Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference 9:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
XYDALBA™ (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults 4:15 p.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference 9:00 a.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition 7:30 a.m. Dec. 16, 2014 - PR Newswire - PRF
Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA® IR 3:11 p.m. Dec. 15, 2014 - PR Newswire - PRF
Actavis Launches Generic Version of Celebrex® 9:28 a.m. Dec. 10, 2014 - PR Newswire - PRF
Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam 4:46 p.m. Dec. 5, 2014 - PR Newswire - PRF
No Wrinkles in Actavis' $66 Billion Deal to Buy Botox Maker Allergan, an Industrial Info News Alert 6:15 a.m. Dec. 3, 2014 - Marketwired
Stock Updates on Pharma Services - Avanir Pharma, Zoetis, Allergan, Mallinckrodt, and Actavis 8:30 a.m. Nov. 25, 2014 - PR Newswire - PRF
Actavis expects profit to beat expectations 9:44 a.m. Jan. 12, 2015 - Michael Calia
Drug trials, upgrades boost health-care sector 11:57 a.m. Jan. 8, 2015 - Russ Britt
10 stocks that can withstand a rocky 2015 12:31 p.m. Dec. 31, 2014 - The Trading Deck
Eight charts plot the year in finance 12:45 p.m. Dec. 30, 2014 - Ophir Gottlieb
Here are the best S&P 500 stocks and sectors of 2014 1:52 p.m. Dec. 29, 2014 - Philip van Doorn
2014 was the year that all predictions were wrong 11:29 a.m. Dec. 26, 2014 - Marek Fuchs
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Adamas' stock soars after dementia treatment approval 8:24 a.m. Dec. 24, 2014 - Tomi Kilgore
Second 2% S&P 500 spike signals strong bull trend 11:23 a.m. Dec. 19, 2014 - Michael Ashbaugh
What a week: Botox haze, merger Monday and The Tanned One 9:19 a.m. Nov. 21, 2014 - Marek Fuchs
Valeant's stock rises after new $2 billion buyback plan announced 12:00 p.m. Nov. 20, 2014 - Tomi Kilgore
La-Z-Boy shares rally after earnings beat targets 4:41 p.m. Nov. 18, 2014 - Sue Chang
S&P, Dow ring up records Tuesday 4:35 p.m. Nov. 18, 2014 - Barbara Kollmeyer
Actavis shares outpace buyout target’s gains 12:30 p.m. Nov. 18, 2014 - Russ Britt
S&P 500 registers 42nd record close in skittish market 4:59 p.m. Nov. 17, 2014 - Carla Mozee
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
Valeant says it won’t meet Actavis’s offer 12:18 p.m. Nov. 17, 2014 - Russ Britt
If you're looking big pharma, look no further than Actavis 11:33 a.m. Nov. 17, 2014 - The Trading Deck
Actavis to buy Allergan in $66 billion deal 9:35 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Actavis confirms to buy Allergan in $66 billion deal 9:30 a.m. Nov. 17, 2014 - Ciara Linnane
Celgene, Bristol-Myers Cancer Drug News Lifts Stocks 5:48 p.m. Jan. 12, 2015 - Investors Business Daily
Celgene Says Q4 Earnings Beat, Sees Currency Impact 12:52 p.m. Jan. 12, 2015 - Investors Business Daily
3 Stocks Advancing The Drugs Industry 12:13 p.m. Jan. 12, 2015 - TheStreet.com
Digging Deeper: Outperforming Stocks In The Leading Health Care Sector 12:10 p.m. Jan. 12, 2015 - Seeking Alpha
FTC grants early termination of HSR waiting period for Actavis/Allergan deal 9:34 a.m. Jan. 12, 2015 - Seeking Alpha
Actavis Profit to Beat Expectations 9:21 a.m. Jan. 12, 2015 - The Wall Street Journal Interactive Edition
Actavis (ACT) Off To A Strong Start In Pre-Market Activity 9:10 a.m. Jan. 12, 2015 - TheStreet.com
Four Best Gains In IBD 50: Nothing To Do With Oil 5:35 p.m. Jan. 9, 2015 - Investors Business Daily
Jim Cramer's 'Mad Money' Recap: You'll Make More Money Buying Into Panic 8:23 p.m. Jan. 8, 2015 - TheStreet.com
Four Hot Growth Stocks To Put On Your Watch List 5:06 p.m. Jan. 8, 2015 - Investors Business Daily
Adamas earns milestone from Actavis 4:19 p.m. Jan. 8, 2015 - Seeking Alpha
Actavis' Appeal Case for Namenda Gets Accelerated Hearing - Analyst Blog 4:35 p.m. Jan. 7, 2015 - Zacks.com
KaloBios Pharmaceuticals' KB001-A Fails Primary Endpoint - Analyst Blog 2:28 p.m. Jan. 7, 2015 - Zacks.com
10 Stocks Every Millennial Should Add to Their Portfolio Right Now 11:37 a.m. Jan. 7, 2015 - TheStreet.com
Health-Care Stocks Avoid Malaise 8:34 p.m. Jan. 6, 2015 - The Wall Street Journal Interactive Edition
Will Allergan Buy Help Actavis Extend Growth Streak? 5:17 p.m. Jan. 6, 2015 - Investors Business Daily
Merger Arbitrage Mondays - January 5, 2015 6:34 a.m. Jan. 5, 2015 - Seeking Alpha
IBD 50 Tone Darkens; More Leaders Below 10-Week Line 5:13 p.m. Jan. 2, 2015 - Investors Business Daily
An Investor's Guide: Market-Leading Industries In 2014 1:57 p.m. Jan. 2, 2015 - Investors Business Daily
Activists Are on a Roll, With More to Come 5:08 p.m. Jan. 1, 2015 - The Wall Street Journal Interactive Edition
Actavis Launches U.S. Generic Specialty Injectable Portfolio 8:00 a.m. Today - PR Newswire - PRF
Equities Updates on Health Care Sector - Johnson and Johnson, VIVUS, Actavis, Covance, and Sequenom 8:35 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis Announces Exceptional Preliminary Fourth Quarter 2014 Performance 8:30 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis’ Pending Acquisition of Allergan and Record Dates for Shareholder Meetings 8:02 a.m. Jan. 12, 2015 - BusinessWire - BZX
Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis' Pending Acquisition of Allergan and Record Dates for Shareholder Meetings 8:00 a.m. Jan. 12, 2015 - PR Newswire - PRF
Actavis Confirms Appeals Court Grants Expedited Appeal of Ruling Requiring Continued Distribution of NAMENDA® IR 3:54 p.m. Jan. 6, 2015 - PR Newswire - PRF
Actavis and Gedeon Richter Announce FDA Receipt of NDA Resubmission for Cariprazine 2:00 a.m. Jan. 6, 2015 - PR Newswire - PRF
Timing is Crucial, Upside Analysis: Research Reports on Alder, Sky Solar, CNinsure, Raytheon, and Actavis 9:00 a.m. Dec. 29, 2014 - PR Newswire - PRF
Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 1:15 p.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride 8:00 a.m. Dec. 24, 2014 - PR Newswire - PRF
Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer 9:24 a.m. Dec. 22, 2014 - PR Newswire - PRF
Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference 9:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
XYDALBA™ (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults 4:15 p.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference 9:00 a.m. Dec. 19, 2014 - PR Newswire - PRF
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition 7:30 a.m. Dec. 16, 2014 - PR Newswire - PRF
Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA® IR 3:11 p.m. Dec. 15, 2014 - PR Newswire - PRF
Actavis Launches Generic Version of Celebrex® 9:28 a.m. Dec. 10, 2014 - PR Newswire - PRF
Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam 4:46 p.m. Dec. 5, 2014 - PR Newswire - PRF
No Wrinkles in Actavis' $66 Billion Deal to Buy Botox Maker Allergan, an Industrial Info News Alert 6:15 a.m. Dec. 3, 2014 - Marketwired
Stock Updates on Pharma Services - Avanir Pharma, Zoetis, Allergan, Mallinckrodt, and Actavis 8:30 a.m. Nov. 25, 2014 - PR Newswire - PRF
(0)
(0)